Area of research
Physiology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Asthma and respiratory diseases, Chronic Obstructive Pulmonary Disease (COPD) Research, Delphi Technique in Research, and Respiratory and Cough-Related Research.
Clustering of the Bronchial Epithelial Immune Response to Viral Stimulation in Patients With Asthma Identifies Clinically Recognisable Epithelial Exacerbation Response Profiles.
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial
Use of High-Dose Inhaled Corticosteroids and Risk of Corticosteroid-Related Adverse Events in Asthma Findings From the NORDSTAR Cohort
Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics
Personalized therapeutic approaches for asthma
International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update
Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial
Early Reduction of FeNO on Anti-IL5 Biologics Is Associated With Clinical Remission of Severe Asthma.
International Severe Asthma Registry (ISAR): 2017-2024 Status and Progress Update.
Long‐Term, Real‐World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma
Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities.
The impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma.
Long-Term, Real-World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma.
Le dupilumab réduit l’obstruction et le volume du mucus : essai de phase 4 VESTIGE
Airway hyperresponsiveness in asthma: The role of the epithelium
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma
Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort
Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthma.
Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma
Biomarkers and clinical outcomes after tezepelumab cessation
Real-world biologics response and super-response in the International Severe Asthma Registry cohort.
Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients with Uncontrolled Moderate-To-Severe Asthma: the VESTIGE Trial
Dupilumab reduces mucus plugging and volume: phase 4 VESTIGE trial
Effect of Dupilumab Treatment on Mucus Plugging and Mucus Volume in Type 2 Asthma: The Phase 4 VESTIGE Trial
Early treatment response to dupilumab on airway inflammation, airway dynamics, and mucus plugging in VESTIGE
Évaluation de l’effet du dupilumab sur l’inflammation de type 2 des voies respiratoires et le bouchon de mucus chez les patients souffrant d’asthme modéré à sévère non contrôlé : l’essai VESTIGE
Correspondence: “The effectiveness of pollen allergen immunotherapy on allergic rhinitis over 18 years: A national cohort study in Denmark”
S95 Effect of dupilumab treatment on mucus plugging and mucus volume in type 2 asthma: the phase 4 VESTIGE trial